A compounded form of imiquimod, a topical immune response modifier, showed promise as a treatment for ocular surface ...

The FDA has approved durvalumab plus fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy as neoadjuvant and ...

November 2025 saw pivotal FDA approvals, including durvalumab for gastric cancers and pembrolizumab/enfortumab vedotin for ...

The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

AstraZeneca’s Imfinzi approved in US as first and only perioperative immunotherapy for patients with early gastric and GEJ cancers: Cambridge, UK Thursday, November 27, 2025, 09 ...

AstraZeneca’s Imfinzi (durvalumab), in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel), has been approved by the US FDA to treat adult ...

The US Food and Drug Administration approved AstraZeneca’s Imfinzi (durvalumab) with fluorouracil, leucovorin, oxaliplatin, ...

Keytruda plus platinum-based chemotherapy was found to be both safe and efficacious in treating penile squamous cell carcinoma (PSCC), according to findings from the phase 2 HERCULES trial presented ...

Findings from the phase 3 MATTERHORN trial supported the FDA approval of perioperative durvalumab for resectable gastric and GEJ cancers.

The FDA approved perioperative durvalumab (Imfinzi) in combination with a multidrug chemotherapy regimen for resectable ...

The FDA has approved AstraZeneca’s IMFINZI combined with standard FLOT chemotherapy for adults with resectable, early-stage ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy ...